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A B S T R A C T
Purpose
The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguish-
ing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study
examined the clinical relevance of such a distinction.
Methods
Representatives from seven international centers of excellence for myeloproliferative neo-
plasms convened to create a clinicopathologic database of patients previously diagnosed as
having ET (N  1,104). Study eligibility criteria included availability of treatment-naive BM
specimens obtained within 1 year of diagnosis. All bone marrows subsequently underwent a
central re-review.
Results
Diagnosis was confirmed as ET in 891 patients (81%) and was revised to early/prefibrotic PMF
in 180 (16%); 33 patients were not evaluable. In early/prefibrotic PMF compared with ET, the
10-year survival rates (76% and 89%, respectively) and 15-year survival rates (59% and 80%,
respectively), leukemic transformation rates at 10 years (5.8% and 0.7%, respectively) and 15
years (11.7% and 2.1%, respectively), and rates of progression to overt myelofibrosis at 10
years (12.3% and 0.8%, respectively) and 15 years (16.9% and 9.3%) were significantly
worse. The respective death, leukemia, and overt myelofibrosis incidence rates per 100
patient-years for early/prefibrotic PMF compared with ET were 2.7% and 1.3% (relative risk
[RR], 2.1; P  .001), 0.6% and 0.1% (RR, 5.2; P  .001), and 1% and 0.5% (RR, 2.0; P  .04).
Multivariable analysis confirmed these findings and also identified age older than 60 years
(hazard ratio [HR], 6.7), leukocyte count greater than 11  109/L (HR, 2.01), anemia (HR, 2.95),
and thrombosis history (HR, 2.81) as additional risk factors for survival. Thrombosis and
JAK2V617F incidence rates were similar between the two groups. Survival in ET was similar
to the sex- and age-standardized European population.
Conclusion
This study validates the clinical relevance of strict adherence to WHO criteria in the diagnosis of
ET and provides important information on survival, disease complication rates, and prognostic
factors in strictly WHO-defined ET and early/prefibrotic PMF.
J Clin Oncol 29:3179-3184. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Thedifferential diagnosis of increasedplatelet count
includes reactive thrombocytosis, essential thrombo-
cythemia (ET), chronic myelogenous leukemia, poly-
cythemia vera (PV), primary myelofibrosis (PMF),
refractory anemia with ring sideroblasts and
marked thrombocytosis, and other chronic my-
eloid neoplasms.1 Accurate diagnosis is important
in termsofbothprognosticationand treatment.The
WHO classification system for hematopoietic tu-
morsprovides clear andconciseguidelines indistin-
guishing ET from both reactive thrombocytosis
and other myeloid neoplasms.1 Accordingly, the
presence of a clonal marker (eg, JAK2 orMPLmu-
tation), which is present in the majority of patients
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with ET, PV or PMF, reliably excludes the possibility of reactive
thrombocytosis, whereas chronic myelogenous leukemia and re-
fractory anemia with ring sideroblasts andmarked thrombocytosis
are expected to be invariably associated with BCR-ABL1 and dys-
erythropoiesis, respectively.2 It should be noted, however, that
JAK2V617F, which is the most frequent mutation in BCR-ABL1–
negative myeloproliferative neoplasms (MPNs), has limited dis-
criminatory value.3,4 Bone marrow (BM) histology, including
megakaryocyte morphology and degree of myeloproliferation, is
key in distinguishing ET from the prodromal stages of PV and
PMF.5 Overt BMfibrosismight be absent in early/prefibrotic PMF,
leading to a spurious diagnosis of ET if one does not pay attention
to BMmorphology. This study was performed under the auspices
of the InternationalWorking Group forMPNResearch and Treat-
ment; themain objective of the studywas to address the prognostic
relevance of distinguishing early/prefibrotic PMF associated with
thrombocytosis from ET.
METHODS
Physician scientists and hematopathologists from seven international centers
of excellence for MPNs convened to create a clinicopathologic database of
patientswhowere diagnosed and treated for ET in their respective locales. The
studywas approvedby the institutional reviewboardof each institution. Study
eligibility criteria included the availability of representative, treatment-naive
BM biopsies obtained at diagnosis or within 1 year of diagnosis. Diagnostic
criteria used were those in effect at the time of initial diagnosis; in most
instances, the Polycythemia Vera StudyGroup criteria6 were used for diagno-
ses made before 2002, and the WHO criteria were used for diagnoses made
thereafter.7,8 However, before central re-review, the local hematopatholo-
gists from each study center were given the opportunity to revise the
diagnoses from their older BM slides (hematoxylin-eosin staining and
silver impregnation after Gomori or Gordon-Sweet) according to the
updated 2008 WHO criteria.8
All BM biopsies subsequently underwent a central re-review by one of
the authors (J.T.),who is a coinvestigator in this project aswell as the author of
the WHO chapter on diagnostic criteria for PMF, PV, and ET.8 The final
diagnostic assignment was made according to the results of the central re-
review. In the course of this review, corresponding guidelines to recognize
characteristic histologic BMpatterns, including fiber scoring,9 were applied to
identify occurrences of early/prefibrotic PMF that were spuriously diagnosed
as ET. Both local pathologists and the expert reviewer had access to patient
information that is necessary for routine interpretation of BM morphology.
However, the review process was completely blinded to outcome data,
which were analyzed after the completion of the histopathology review.
The diagnosis of post-ET myelofibrosis (or progression into overt myelo-
fibrosis) wasmade by corresponding clinical features, includingworsening
anemia, splenomegaly, leukoerythroblastosis, or anisopoikilocytosis with
teardrop erythrocytes. Leukemic transformation met criteria for acute
myeloid leukemia per the WHO system.7,8 Allele-specific polymerase
chain reaction techniques were utilized to screen for JAK2V617F in each
participating center.10-12
A total of 116 disease-relevant parameters were extracted in each occur-
rence; these parameters included dates of diagnosis, death, leukemic trans-
formation, progression into overt myelofibrosis, and vascular events. All
statistical analyses considered parameters at the time of initial diagnosis. Dif-
ferences in the distribution of continuous variables between categories were
analyzed by the Mann-Whitney test. Patient groups with nominal variables
were compared by the 2 test. Outcomes of interest were reported as rates per
100patient-years aswell as by cumulative incidences calculated at 5, 10, and15
years from the date of diagnosis. Incidence rate ratios between groups were
estimated and tested.Overall survival analysis was considered from the date of
diagnosis to date of death (uncensored) or last contact (censored). Leukemia-
free, overt myelofibrosis-free, and thrombosis-free survivals were calculated
from the date of diagnosis to date of leukemic transformation, progression
into overt myelofibrosis, and thrombotic complication (all uncensored), re-
spectively, or last contact/date of death (all censored). Survival estimates
patients with ET and early-PMF were compared with those obtained by
applying to the population the 2008 Eurostat age- and sex-standardized
incidence rates for all causes of death, by using the indirect standardization
procedure. All survival curves were prepared by the Kaplan-Meier method
and were compared by the log-rank test. The Cox proportional hazard
regressionmodel was used for multivariable analysis. P values less than .05
were considered significant.
RESULTS
A total of 1,104 patients met minimal criteria for study inclusion: a
local diagnosis of ET with pretreatment BM obtained at time of diag-
nosis or within 1 year of diagnosis. All occurrences were diagnosed
between 1975 and 2008 and were recruited from Pavia, Italy (n 
271), Bergamo, Italy (n 186), Vicenza, Italy (n 152), Rochester,
MN(n130), Padua, Italy (n123),Vienna,Austria (n122), and
Florence, Italy (n  120). Central re-review led to a diagnosis of
Table 1. Comparison of Patient Characteristics at Presentation in ET Versus
Early/Prefibrotic PMF
Characteristic ET (n  891)
Early/Prefibrotic
PMF (n  180) P
Age, years .66
Median 56 57
Range 13-91 21-88
Sex
Male 370 74
Female 521 106 .92
Leukocyte count, 109/L  .001
Median 8.6 9.7
Percentile range, 5th to 95th 5.3-14.2 6.9-17.0
Hemoglobin, g/dL .01
Median 14.1 13.8
Percentile range, 5th to 95th 11.9-16.1 11.4-15.8
Platelets, 109/L .002
Median 774 902
Percentile range, 5th to 95th 500-1,464 564-1,898
Lactate dehydrogenase, mU/mL  .001
Median 298 429
Percentile range, 5th to 95th 150-582 121-875
Palpable splenomegaly .04
No. 146 41
% 16 23
Circulating CD34 cell count/L† .03
Median 2 4.7
Range 0-15.2 0-60
JAK2V617F positive‡ .56
No. 422 67
% 61 58
Reticulin fibrosis grade 19  .001
No. 24 43
% 3 24
Abbreviations: ET, essential thrombocythemia; PMF, primary myelofibrosis.
No. of patients  519.
†No. of patients  246.
‡No. of patients  805.
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WHO-defined ET in 891 instances (81%) and early/prefibrotic PMF
in 180 (16%); the remaining 33 (3%) BM specimens were either
qualitatively inadequate for accurate classification or represented re-
active occurrences. The concordance rate for the diagnosis of ET
between the seven local pathologists and the referee pathologist was
81%when considering the total study cohort, includingnonrepresen-
tative biopsy samples, andwas 83% for discriminating ET from early/
prefibrotic PMF.
Patient Characteristics at Presentation
Table 1 provides a comparative illustration of presenting clinical
and laboratory features for 891 patientswith ET and 180 patientswith
early/prefibrotic PMF. Significant differences were seen for leukocyte
count (greater in early/prefibrotic PMF than ET), hemoglobin level
(greater in ET than early/prefibrotic PMF), platelet count (greater in
early/prefibrotic PMF than ET), serum lactate dehydrogenase (LDH)
level (greater in early/prefibrotic PMF than ET), circulatingCD34 cell
count (greater in early/prefibrotic PMF than ET), incidence of palpa-
ble splenomegaly (greater in early/prefibrotic PMF than ET), and
frequency of grade 1 BM fibrosis (greater in early/prefibrotic PMF
than ET). Of note, age and sex distribution and JAK2V617F muta-
tional frequencies were similar between the two groups.
Clinical Course of Patients With ET Versus
Early/Prefibrotic PMF
Median follow-up from time of diagnosis was 6.2 years (range, 0
to 27 years) for ET and 7 years (range, 0 to 27.2 years) for early/
prefibrotic PMF (P .3). During this period, 87 patients (10%) with
ET and 40 (22%) with early/prefibrotic PMF had died (P  .001).
Cytoreductive therapy was instituted in 507 patients (57%) with ET
and in 123 (68%) with early/prefibrotic PMF (P  .005). In total,
leukemic and overt fibrotic transformations were documented in
eight patients (1%) and 32 patients (4%), respectively, with ET and in
nine patients (5%) and 14 patients (8%), respectively, with early/
prefibrotic PMF (P .0012 for leukemic transformation; P .04 for
overt fibrotic transformations; Table 2). In contrast, the incidences of
thrombotic complications were similar between the two groups: 109
(12%) in ET and 26 (15%) in early/prefibrotic PMF (P  .51). The
15-year cumulative risks of death, leukemic transformation, overt
fibrotic progression, and thrombotic complications were approxi-
mately 25%, 2%, 9%, and 22%, respectively, for ET and were 56%,
12%, 17%, and25%, respectively, for early/prefibrotic PMF (Table 2).
Overall (Fig 1A;P .001), leukemia-free (Fig 1B;P .001) and overt
myelofibrosis–free (Fig 1C;P .03) survivalswere significantly better
inET than in early/prefibrotic PMF,whereas thrombosis-free survival
was similar in the two groups (Fig 1D). Median overall survival was
11.2 years for early/prefibrotic PMFandwas 14.7 years ET (P .001).
Survival in ET was similar to that of the sex- and age-standardized
European population (Fig 2).
Multivariable Analysis of Overall and
Event-Free Survival
Multivariable analysis was performed on data from all 1,071
study patients by using Cox regression model and included several
covariateswithpotential prognostic relevance:BMhistopathology (ie,
ET v early/prefibrotic PMF), age (older than 60 years), sex, history of
thrombosis, leukocytosis ( 11 109/L), anemia, extreme thrombo-
cytosis (platelet count1,000109/L), JAK2V617F, andgrade 1BM
reticulin fibrosis (Table 3). Of note, the threshold level of 11,000 
109/L leukocyteswas chosen on the basis of receiver operating charac-
teristic (ROC) analysis.
The prognostic relevance of BMhistopathology remained signif-
icant for survival (P .03), leukemic transformation (P .007) and
overt fibrotic progression (P .019). In addition, survival was inde-
pendently andnegatively affectedbyolderage (ageolder than60years;
P  .001), leukocytosis (leukocyte count  11  109/L; P  .001),
anemia (hemoglobin 12 g/dL; P .001) and history of thrombosis
(P  .001). BM histopathology–independent risk factors for overt
fibrotic progression included older age, anemia, and, interestingly,
absence of JAK2V617F (Table 3). The corresponding risk factors for
leukemic transformation were history of thrombosis and extreme
thrombocytosis (Table 3).
DISCUSSION
BCR-ABL1 and JAK2V617F mutation screening have helped over-
come some of the diagnostic uncertainties in ET.2 However, the mo-
lecular and phenotypic similarities between ET and early/prefibrotic
Table 2. Comparison of Disease Complications During Follow-Up in ET Versus Early/Prefibrotic PMF
Event
No. of
Events
% of
Events
Incidence per
100 Patient-Years IRR P
5-Year Cumulative
Incidence (%)
10-Year Cumulative
Incidence (%)
15-Year Cumulative
Incidence (%)
Thrombosis
ET 109 12 1.7 1.1 .57 8.7 16.2 21.5
Early/prefibrotic PMF 26 15 1.9 6.6 17.9 25.4
Transformation to overt
myelofibrosis
ET 32 4 0.5 2.0 .04 0.2 0.8 9.3
Early/prefibrotic PMF 14 8 1 2.3 12.3 16.9
Leukemic transformation
ET 8 1 0.1 5.2 .0012 0.2 0.7 2.1
Early/prefibrotic PMF 9 5 0.6 1.5 5.8 11.7
Death
ET 87 10 1.3 2.1 .0002 3.0 14.8 24.6
Early/prefibrotic PMF 40 22 2.7 8.6 24.4 56.1
Abbreviations: ET, essential thrombocythemia; PMF, primary myelofibrosis; IRR, incidence rate ratio.
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PMF have led to significant controversies and speculations regarding
the value of morphology in distinguishing between the two entities
and the clinical relevance of such an exercise.13-15 In this regard, it
should be noted that, independent from theCologne groupwhowere
instrumental in the original description of the key histologic differences
between ET and early/prefibrotic PMF,5 several other investigators had
endorsed the reliability of BMmorphologic and histopathologic charac-
teristicsproposedbytheWHO.16-19Ontheotherhand, twoothergroups
haveraisedthe issueofreproducibility inthismatter.14,15Thestudybythe
English group14 includeda semiquantitative evaluationof approximately
16 BM parameters in 370 biopsy specimens derived from the United
Kingdom-PT1 trial20 and is, unfortunately, impaired by a number of
inconsistencies in design and performance that have been already dis-
cussed elsewhere.5 In the other study by a French group,15 the authors
claimed to have applied theWHOclassification for ETbut described the
presence of a minor to moderate reticulin fibrosis in 54% of their BM
biopsies obtained up to 3 years after diagnosis. This is inconsistent with
what is expected ifonewere to strictly adhere toWHOdiagnostic criteria,
in which minor reticulin fibrosis is much less frequent (Table 1).13 Re-
gardless, themore than80%concordance ratebetween local pathologists
and the referee pathologist in this study compares favorably with other
reportedconcordance rates related to thediagnosis ofhistologically com-
plex hematopoietic disorders.21,22 Furthermore, our observation that
16%ofEToccurrences recruited fromseveralMPNcenters of excellence
represented misdiagnosed early/prefibrotic PMF is partly explained by
P < .001
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Fig 1. (A) Overall, (B) leukemia-free, (C) overt myelofibrosis–free, and (D) thrombosis-free survivals of patients with true essential thrombocythemia (ET; n  891)
versus early/prefibrotic primary myelofibrosis (PMF; n  180).
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Fig 2. Survival estimates for patients with essential thrombocythemia (ET)
and early/prefibrotic primary myelofibrosis (PMF) were compared with those
obtained by applying to the population the 2008 Eurostat age- and sex-
standardized incidence rates for all causes of death, by using the indirect
standardization procedure.
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the inclusion of patients diagnosed before 2002, when the now-defunct
Polycythemia Vera Study Group diagnostic criteria6 were utilized; the
latter did not emphasizemorphologic scrutiny and instead reliedmostly
on extent of BMfibrosis to distinguishET fromPMF.23
The main objective of this study was to address the clinical rele-
vanceofdistinguishingWHO-definedET fromearly/prefibroticPMF
by subjecting a large number of ET occurrences to a central review of
BMmorphologyandsubsequentlybycomparingclinicalpresentation
and outcome data between confirmed ET occurrences and those pa-
tientswhose diagnoseswere revised to early/prefibrotic PMF.Accord-
ingly, the latter group is not precisely representative of early/
prefibrotic PMF, and this study design may not provide definitive
conclusions about differences in the evolution of ET and early/prefi-
brotic PMF. Regardless, the results of this study indicate that the
distinction between ET and early/prefibrotic PMF is not trivial and
that accurate diagnosis is prognostically relevant. At the same time,
one should note that, although inferior to that seen in patients with
ET, event-free survival was still relatively long in patients with early/
prefibrotic PMF. This study also provides laboratory clues for consid-
ering the possibility of early/prefibrotic PMF: elevated serum LDH,
anemia, leukocytosis, and increased circulating CD34 cell count.
Accordingly, the appearance of such characteristics during the clinical
course of ET might be considered as an indication for repeating BM
examination to entertain the possibility of overt fibrotic transforma-
tion. JAK2V617Fmutational frequencieswere similarbetweenETand
early/prefibrotic PMF, although another recent study had suggested a
higher mutant allele burden in the latter.24
Given the more aggressive disease biology in non-ET myeloid
neoplasms, which might mimic ET in their clinical presentations, it
was our hypothesis that survival and disease complication rates in
strictly WHO-defined ET would be even more favorable than cur-
rently assumed. The results of this study support this contention by
revealing a less than 1% 10-year risk of leukemic or overt fibrotic
transformation in morphologically accurate ET. These figures are
notably lower than those previously reported in large retrospective
studies from independent groups of investigators. For example, in a
recent population-based French study of 311 patients with ET, the
10-year risk of leukemic transformation was reported as 8.3%25; in
anothermulticenter studyof 211patients fromChina, the 10-year risk
of overt fibrotic transformation was reported as 9.7%,26 and the cor-
responding figure from a Spanish series was 8.3%.27 Therefore, it is
reasonable to assume that data from previous natural history studies
inETareconfoundedby the inadvertent inclusionofoccurrenceswith
early/prefibrotic PMF and do not necessarily apply to patients whose
diagnoses are based on strict morphologic criteria. In instances for
which an attempt was made to re-review BM histopathology accord-
ing to WHO criteria, reported disease complication rates were closer
to those fromthis study28,29: 10-year riskof leukemicandovertfibrotic
transformation rates were 1.4% and 3.8%, respectively, in one such
study fromtheMayoClinic29 andwere2.6%and3.9%,respectively, in
another study from Pavia, Italy.28
Multivariable analyses in this study confirmed the prognostic
relevance of BM histopathology for survival, leukemic transforma-
tion, and overt fibrotic progression. BMhistopathology–independent
risk factors for survival included older age (older than 60 years),
leukocytosis (leukocyte count  11  109/L), anemia (hemoglobin
 12 g/dL), and thrombosis history.Not surprisingly, all four of these
risk factorswerepreviously cited in the samecapacity, although incon-
sistently, by other studies.25,26,28-31 Someof these previous studies had
also reported a similar adverse survival effect from tobaccouse, diabe-
tesmellitus, andmale sex. In this study,olderageandanemiawerealso
shown to be independent risk factors for overt fibrotic progression,
and thrombosis history and extreme thrombocytosis were indepen-
dent risk factors for leukemic transformation. In previous studies, risk
factors for leukemic transformation had included leukocytosis, ex-
treme thrombocytosis, andolder age28,30; risk factors for overt fibrotic
progression includedanemia, increased serumLDH, increased reticu-
linfibrosis, andmalesex.28,32Takentogether, it isreasonabletoconclude
thatsomeoftheaforementionedriskfactors(eg,anemia, increasedserum
LDH, leukocytosis, extreme thrombocytosis)might bemarkers of occult
early/prefibrotic PMF, and that could explain their associationwith infe-
rior survival or higher risk of disease progression.
The observations from this study constitute good news for pa-
tients with strictly WHO-defined ET; their prognoses might be even
better than previously assumed (Fig 2). Of note, the presence of
JAK2V617F in this study was not detrimental to survival or leukemic
transformation and was instead associated with a lower risk of overt
fibrotic progression. This study signifies the importance of excluding
early/prefibroticPMF inall patientswithET, especially in thepresence
of proven surrogate markers, such as characteristic BMmorphology,
elevated serumLDH, anemia, or leukocytosis. In this regard, the issue
is not as much about reproducibility of morphologic interpretation
Table 3. Results of Cox Multivariable Analysis of Relevant Clinical and Laboratory Parameters on Rates of Death or Progression to Leukemia or
Overt Myelofibrosis
Parameter at Diagnosis
Progression to Myelofibrosis Leukemic Transformation Death
HR 95% CI P HR 95% CI P HR 95% CI P
BM histology: early/prefibrotic PMF v ET 2.35 1.15 to 4.80 .019 4.50 1.52 to 13.3 .007 1.60 1.05 to 2.44 .030
Age  60 years 2.34 1.28 to 4.30 .006 1.86 0.65 to 5.29 .246 6.70 4.34 to 10.3  .0001
Previous thrombosis 1.14 0.49 to 2.61 .767 4.09 1.40 to 11.9 .010 2.81 1.95 to 4.06  .0001
Male sex 1.68 0.91 to 3.05 .097 1.61 0.59 to 4.38 .350 1.30 0.91 to 1.86 .151
Leukocyte count  11 109/L 0.90 0.42 to 1.93 .781 0.39 0.12 to 1.30 .125 2.01 1.39 to 2.90 .0002
Hemoglobin  12 g/dL 4.22 1.76 to 10.1 .001 2.64 0.49 to 12.4 .274 2.95 1.73 to 5.04  .0001
Platelets  1,000 109/L 0.60 0.30 to 1.23 .165 2.97 1.03 to 8.56 .044 1.30 0.90 to 1.90 .167
JAK2V617F presence 0.37 0.17 to 0.79 .015 1.45 0.23 to 9.17 .693 1.48 0.80 to 2.76 .216
Reticulin fibrosis grade 19 0.94 0.30 to 2.95 .922 1.63 0.41 to 6.5 .49 1.06 0.57 to 1.98 .853
Abbreviations: HR, hazard ratio; BM, bone marrow; PMF, primary myelofibrosis; ET, essential thrombocythemia.
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but more about increased awareness and effective integration of clin-
ical and laboratory data to make an accurate working diagnosis.
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